Creyon Sets the Stage as Oligonucleotide Biotech Partners with Eli Lilly
Deal News | Apr 29, 2025 | DCVC Management Co LLC
Creyon Bio, a biotech startup based in San Diego, has announced a significant partnership with pharmaceutical giant Eli Lilly. The collaboration marks Creyon's first major pharma partnership and illustrates its potential in the oligonucleotide biotechnology sector. The startup is backed by DCVC Management Co LLC, and this development follows the appointment of a new CEO at Creyon. Eli Lilly, headquartered in Indianapolis, recognizes the innovative capabilities of Creyon in developing oligonucleotides, molecules designed to control gene expression, which opens up many therapeutic possibilities.
Sectors
- Biotechnology
- Pharmaceutical
Geography
- United States – Creyon Bio is based in San Diego, California, and Eli Lilly is headquartered in Indianapolis, Indiana, making the United States the central geography for this partnership.
Industry
- Biotechnology – Creyon Bio operates within the biotechnology industry, focusing on oligonucleotide technology, which is used in gene expression control and therapeutic development.
- Pharmaceutical – Eli Lilly is a major player in the pharmaceutical industry, and their partnership with Creyon Bio is a strategic development in their business operations.
Financials
- Not Disclosed – The financial terms of the partnership between Creyon Bio and Eli Lilly have not been publicly disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Creyon Bio | Target Company | Company | A San Diego-based biotech startup focused on developing oligonucleotide technologies. |
| Eli Lilly | Partnering Company | Company | A well-established pharmaceutical company headquartered in Indianapolis, known for its innovation in drug development. |
| DCVC Management Co LLC | Private Equity Firm | Company | A private equity firm that supports innovative startups like Creyon Bio. |